Diane G Carnathan
Overview
Explore the profile of Diane G Carnathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramezani-Rad P, Cottrell C, Marina-Zarate E, Liguori A, Landais E, Torres J, et al.
bioRxiv
. 2025 Feb;
PMID: 39896562
A protective vaccine against HIV will likely need to induce broadly neutralizing antibodies (bnAbs) that engage relatively conserved epitopes on the HIV envelope glycoprotein (Env) trimer. Nearly all vaccine strategies...
2.
Pratap P, Cottrell C, Quinn J, Carnathan D, Bader D, Tran A, et al.
bioRxiv
. 2024 Dec;
PMID: 39651156
During infection, the fusion peptide (FP) of HIV envelope glycoprotein (Env) serves a central role in viral fusion with the host cell. As such, the FP is highly conserved and...
3.
Madden P, Marina-Zarate E, Rodrigues K, Steichen J, Shil M, Ni K, et al.
bioRxiv
. 2024 Dec;
PMID: 39651117
Rare B cells can have special pathogen-recognition features giving them the potential to make outsized contributions to protective immunity. However, rare naive B cells infrequently participate in immune responses. We...
4.
Dankwa S, Kosman C, Dennis M, Giorgi E, Vuong K, Pahountis I, et al.
PLoS One
. 2024 Nov;
19(11):e0312411.
PMID: 39527587
To eliminate vertical HIV transmission and achieve therapy-free viral suppression among children living with HIV, novel strategies beyond antiretroviral therapy (ART) are necessary. Our group previously identified a triple broadly...
5.
Cottrell C, Pratap P, Cirelli K, Carnathan D, Enemuo C, Antanasijevic A, et al.
NPJ Vaccines
. 2024 Jul;
9(1):126.
PMID: 38997302
Immunodominance of antibodies targeting non-neutralizing epitopes and the high level of somatic hypermutation within germinal centers (GCs) required for most HIV broadly neutralizing antibodies (bnAbs) are major impediments to the...
6.
Schiffner T, Phung I, Ray R, Irimia A, Tian M, Swanson O, et al.
Nat Immunol
. 2024 Jun;
25(7):1307.
PMID: 38877179
No abstract available.
7.
Schiffner T, Phung I, Ray R, Irimia A, Tian M, Swanson O, et al.
Nat Immunol
. 2024 May;
25(6):1073-1082.
PMID: 38816615
A key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic diversity is the design of...
8.
Rivera-Hernandez T, Carnathan D, Richter J, Marchant P, Cork A, Elangovan G, et al.
Vaccines (Basel)
. 2024 Apr;
12(4).
PMID: 38675764
Vaccine development against group A (GAS) has gained traction in the last decade, fuelled by recognition of the significant worldwide burden of the disease. Several vaccine candidates are currently being...
9.
DeLuca J, Blasi M, Jha S, Shen X, Pollara J, Kerkau M, et al.
Res Sq
. 2024 Apr;
PMID: 38659814
Diverse and rapidly mutating viruses pose challenges to immunogen and vaccine design. In this study, we evaluated the ability of memory B-cells obtained from two independent NHP trials to cross-react...
10.
Phung I, Rodrigues K, Marina-Zarate E, Maiorino L, Pahar B, Lee W, et al.
Nat Commun
. 2023 Nov;
14(1):7107.
PMID: 37925510
Adjuvants and antigen delivery kinetics can profoundly influence B cell responses and should be critically considered in rational vaccine design, particularly for difficult neutralizing antibody targets such as human immunodeficiency...